AQR Capital Global Equity (S:0P00006W03)
73.70
+0.57
(+0.77%)
USD |
Nov 30 2025
Returns Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Key Stats
Basic Info
| Investment Strategy | |
| None |
| General | |
| Security Type | None |
| Equity Style | None |
| Fixed Income Style | None |
| Broad Asset Class | None |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Fund Owner Firm Name | None |
| Broad Asset Class Benchmark Index | |
| None | |
Annual Total Returns Versus Peers
As of December 28, 2025.
Asset Allocation
| Type | % Net |
|---|---|
| Cash | -- |
| Stock | -- |
| Bond | -- |
| Convertible | -- |
| Preferred | -- |
| Other | -- |
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| Apple, Inc. | 3.83% | 273.40 | -0.15% |
| Microsoft Corp. | 3.30% | 487.71 | -0.06% |
| Meta Platforms, Inc. | 1.58% | 663.29 | -0.64% |
| Alphabet, Inc. | 1.44% | 313.51 | -0.18% |
| Pfizer Inc. | 1.41% | 25.09 | 0.24% |
| Amazon.com, Inc. | 1.38% | 232.52 | 0.06% |
| Repsol SA | 1.36% | 17.81 | 0.00% |
| Exxon Mobil Corp. | 1.32% | 119.11 | -0.09% |
| Citigroup, Inc. | 1.32% | 120.42 | -0.94% |
| CVS Health Corp. | 1.30% | 79.61 | 0.62% |
Fees & Availability
| Fees | |
| Negotiable Fee | -- |
| Maximum Management Fee | -- |
| Prospectus Custodian Fee | -- |
| Purchase Details | |
| Open to New Investors | -- |
Basic Info
| Investment Strategy | |
| None |
| General | |
| Security Type | None |
| Equity Style | None |
| Fixed Income Style | None |
| Broad Asset Class | None |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Fund Owner Firm Name | None |
| Broad Asset Class Benchmark Index | |
| None | |
Fundamentals
| General | |
| Number of Holdings | -- |
| Stock | |
| Weighted Average PE Ratio | -- |
| Weighted Average Price to Sales Ratio | -- |
| Weighted Average Price to Book Ratio | -- |
| Weighted Median ROE | -- |
| Weighted Median ROA | -- |
| Number of Equity Holdings | -- |
Fund Details
| Key Dates | |
| Inception Date | -- |
| Attributes | |
| Socially Responsible Fund | -- |